English
- English
- 中文
ABOUT US
A Global Leader in Integrated Nuclear Medicine
PanMediso is an international enterprise dedicated to advancing precision medicine through end-to-end solutions in radiopharmaceuticals and nuclear medicine technologies, including Ac-225 and Ge-68. We integrate industry, academia, research, diagnostics, and therapy to address critical challenges and drive innovation across the global healthcare landscape.
BUSINESS CAPABILITIES
Medical Isotope Development
Focusing on Ac-225 and Ge-68, we provide end-to-end solutions from isotope R&D and production to radiopharmaceutical assembly.
Clinical Applications & Partnerships
Working independently or with radiopharmaceutical manufacturers, we collaborate with hospitals to deliver nuclear medicine therapies in real-world clinical settings.
CDMO Services
From small-scale lab research to large-scale commercial production, we offer customized manufacturing services to reduce R&D costs and accelerate drug commercialization.
Innovative Radiopharmaceuticals
Our pipeline targets tumor-specific antigens with novel therapies based on Ac-225 and Ge-68, advancing precision diagnosis and treatment in nuclear medicine.
BUSINESS CAPABILITIES
Medical Isotope Development
Focusing on Ac-225 and Ge-68, we provide end-to-end solutions from isotope R&D and production to radiopharmaceutical assembly.
Medical Isotope Development
Focusing on Ac-225 and Ge-68, we provide end-to-end solutions from isotope R&D and production to radiopharmaceutical assembly.
CDMO Services
From small-scale lab research to large-scale commercial production, we offer customized manufacturing services to reduce R&D costs and accelerate drug commercialization.
CDMO Services
From small-scale lab research to large-scale commercial production, we offer customized manufacturing services to reduce R&D costs and accelerate drug commercialization.
Innovative Radiopharmaceuticals
Our pipeline targets tumor-specific antigens with novel therapies based on Ac-225 and Ge-68, advancing precision diagnosis and treatment in nuclear medicine.
Innovative Radiopharmaceuticals
Our pipeline targets tumor-specific antigens with novel therapies based on Ac-225 and Ge-68, advancing precision diagnosis and treatment in nuclear medicine.
Clinical Applications & Partnerships
Working independently or with radiopharmaceutical manufacturers, we collaborate with hospitals to deliver nuclear medicine therapies in real-world clinical settings.
Clinical Applications & Partnerships
Working independently or with radiopharmaceutical manufacturers, we collaborate with hospitals to deliver nuclear medicine therapies in real-world clinical settings.
GLOBAL PRESENCE
GLOBAL PRESENCE
Committed to Building the Integration of Industry, Academia, Research, Diagnosis and Treatment for Nuclear Medicine as an International Enterprise
Isotope Supply
Production Facilities
Sales Center
R&D Center
International Operations
Isotope Supply
Production Facilities
Sales Center
R&D Center
International Operations
NEWS CENTER
-
The signing ceremony of Pamedic Holdings' project was successfully held in Shenzhen.
On November 24th, the signing ceremony of Pamedic Holdings, organized by the host company Pamedic Holdings (Shenzhen) Co., Ltd. and co-organized by C Cheng Holdings Co., Ltd., took place at the Yangtze Hall of Wuzhou Guest House in Shenzhen, Guangdong Province.
View Details -
Pamedic Moment | Jonathan Sackier in Interview, “Dedicated to Cancer Treatment for Chinese”
Jonathan Sackier, the Chief Medical Officer of Pamedic Holdings Limited（hereinafter “PMHL”）:We will deepen our collaboration with Shenzhen and the entire China, dedicated to providing innovative treatment solutions for 8 million Chinese and even global cancer patients.
View Details -
Pamedic Moment | Exploring Actinium in Radiopharmaceuticals[225Ac]
Radiopharmaceuticals, the new star in medical field nowadays, are gradually ejec
View Details -
Pamedic Moment | Project of Medical Isotopes Preparation via Accelerator Kicks Off
Resource: www.xinhuanet.com On 28th March, the signing ceremony for the R&D Proj
View Details -
Pamedic Moment｜Focusing on Nuclear Medicine, The Hong Kong Polytechnic University and Pamedic Holdings Enter into a Partnership
On May 16th, the 4th Asia Summit on Global Health was held at the Hong Kong Conv
View Details -
Pamedic Moment｜An Asian Company Achieves Breakthrough in the Key Technology of Ac-225 Preparation
An Asian Company Achieves Breakthrough in the Key Technology of Ac-225 Preparati
View Details -
Pamedic Moment｜An Asian Company Achieves Breakthrough in the Key Technology of Ac-225 Preparation
August 14, 2025 — Beijing, China. Pamedic, An Asian Company Conquers Ac-225 Core Technology, Tsinghua and Pamedic Solve Global Cancer Isotope Dilemma.
View Details
![Pamedic Moment | Exploring Actinium in Radiopharmaceuticals[225Ac]](https://gcdn.meidianbang.cn/comdata/81850/202402/20240204111526bd6d9e.jpg "Pamedic Moment | Exploring Actinium in Radiopharmaceuticals[225Ac]")
-
Radioligand Therapy: Opening a new chapter in Chinese medical innovation
Novartis recently announced its investment in a new radiopharmaceutical production facility in Haiyan County, Zhejiang Province, China. The total investment is expected to exceed 600 million yuan. The move is aimed at accelerating the introduction of innovative radioligand therapy to meet the clinical needs of cancer patients in the country. Production is expected to begin by the end of 2026, subject to regulatory approval. As a global leader in the pharmaceutical industry, Novartis' investment
View Details -
Pamedic Focuses on Ongoing Innovation in the Radioisotope Pharmaceutical Field
Pamedic Holdings has been dedicated to the research and innovation of isotope core drugs, continuously monitoring and supporting innovative developments within the industry. Recently, innovative news in the isotope field has garnered strong attention in the nuclear medicine sector.
View Details -
Pamedic Spotlight｜Forging a "Golden Age" for China's Nuclear Pharmaceutical Sector
China's nuclear medicine market size keeps growing, according to industry foreca
View Details -
Pamedic Spotlight｜What is Radiopharmaceuticals to Patients
Radiopharmaceuticals, as a key component in the field of molecular imaging
View Details -
Pamedic Spotlight｜Performance Comparison between α-isotopes and β-isotopes
As medical science and technology develops, radioisotope therapy has become an i
View Details -
Pamedic Spotlight｜Interpretation of the Technical Guidelines for Non-clinical Studies of Therapeutic Radiopharmaceuticals
On 22.1.2024, Center For Drug Evaluation issued the Technical Guidelines for Non
View Details -
Pamedic Spotlight｜Dynamics of Radiopharmaceuticals Business
Recently, a number of notable progress have been made in radiopharmaceuticals b
View Details -
Pamedic Spotlight｜Radionuclide Drug Conjugates (RDC): a New Era in Targeted Tumour Therapy
In recent years, Radionuclide-adionuclide Drug Conjugates (RDC) have emerged in
View Details
NEWS CENTER
CONTACT US
Tel. 0755-82567092
Email：pchl@panmedisoholdings.com
Address：Room 406, Building C, Hetao Innovation Center, No.1 Honghua Road, Fubao Sub-district, Futian District, Shenzhen, Guangdong, China
CONTACT US
Address: Room 406, Building C, Hetao Innovation Center, No.1 Honghua Road, Fubao Sub-district, Futian District, Shenzhen, Guangdong, China
Copyright © 2025 PanMediso
SCROLL
